NCT00612950

Brief Summary

The incretin effect is attenuated in patients with type 2 diabetes mellitus partly due to impaired potentiation of beta-cell responsiveness to glucose by glucose dependent insulinotropic polypeptide and glucagon-like peptide-1 respectively. The aim of the present study was to investigate whether 4 weeks of near-normalization of blood glucose could improve the insulin responses to GIP and GLP-1 in patients with type 2 diabetes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for not_applicable type-2-diabetes

Timeline
Completed

Started Oct 2006

Shorter than P25 for not_applicable type-2-diabetes

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2006

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2007

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2007

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

January 16, 2008

Completed
27 days until next milestone

First Posted

Study publicly available on registry

February 12, 2008

Completed
Last Updated

February 12, 2008

Status Verified

January 1, 2008

Enrollment Period

4 months

First QC Date

January 16, 2008

Last Update Submit

February 11, 2008

Conditions

Outcome Measures

Primary Outcomes (1)

  • 2.phase insulin response measured as incremental area under the curve from 10-120 minutes

    2 hours

Secondary Outcomes (1)

  • 2.phase insulin response measured as incremental area under the curve from 10-120 minutes, after 4 weeks of insulin treatment

    2 hours

Study Arms (3)

GLP-1

EXPERIMENTAL
Drug: glucagon-like peptide-1,

GIP

EXPERIMENTAL
Drug: glucose dependent insulinotropic polypeptide

saline

PLACEBO COMPARATOR
Drug: Saline

Interventions

GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.

GLP-1

continuous infusion of GIP (1½ pmol/kg/min) for 120 min.

GIP
SalineDRUG

continuous infusion of Saline for 120 min

saline

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-70 years
  • Type 2 diabetes diagnosed after 30 years of age
  • BMI \> 25

You may not qualify if:

  • Severe complications to diabetes
  • Abnormal liver and kidney function
  • Haemoglobin below the lower limit
  • Macroalbuminuria
  • Systemic disease
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dept. of Endocrinology, Hvidovre Hospital

Copenhagen, Denmark

Location

Related Publications (1)

  • Hojberg PV, Vilsboll T, Rabol R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009 Feb;52(2):199-207. doi: 10.1007/s00125-008-1195-5. Epub 2008 Nov 27.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Glucagon-Like Peptide 1IncretinsSodium Chloride

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Glucagon-Like PeptidesProglucagonGastrointestinal HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Patricia V Højberg, MD, PHD

    University Hospital Hvidovre

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 16, 2008

First Posted

February 12, 2008

Study Start

October 1, 2006

Primary Completion

February 1, 2007

Study Completion

May 1, 2007

Last Updated

February 12, 2008

Record last verified: 2008-01

Locations